“We prioritize working with the best partners in this industry and Novamind’s U.S. platform through eight established, reputable, efficiently operating and revenue-producing clinics,” says Payton Nyquvest, Founder and CEO, Numinus. The Novamind acquisition presents a transformational opportunity for Numinus to launch a strong U.S. “Since Numinus began, we have always strived to be the most trusted, evidence-based leader in psychedelic-assisted therapy and medicine. (“Novamind”) (CSE: NM) (OTCQB: NVMDF) (FSE: HN2), are pleased to announce that they have entered into a definitive arrangement agreement (the “Agreement”) pursuant to which Numinus will acquire all of the issued and outstanding common shares of Novamind (the “Novamind Shares”) in an all-share transaction, by way of a court-approved plan of arrangement, for total consideration of approximately C$26.2 million on a fully diluted in-the-money basis (the “Transaction”).įollowing the Transaction, the combined company will operate 13 wellness clinics and will be positioned as a leading psychedelic-assisted therapy provider in North America, leading its peer group in revenue with approximately C$10 million in annual pro-forma revenue based on the trailing four quarters. (“Numinus”, the “Company”) (TSX: NUMI ) (OTCQX: NUMIF) and Novamind Inc. VANCOUVER, BC and TORONTO, Ap/CNW/ – Numinus Wellness Inc.
Numinus to Acquire Novamind, Creating the North American Industry Leader in Psychedelic Therapy and Research Highlights of the Transaction will also be discussed on Numinus’ upcoming Q2 2022 results conference call, occurring at 5:30 pm ET / 2:30 pm PT on Thursday, April 14, 2022. We are excited to join Numinus, a true leader in mental health innovation.” The combined entity is supported with over C$50 million in pro-forma capital and positioned with distinct capabilities to serve a growing and diverse group of stakeholders. and Numinus’ leadership in psychedelic-assisted psychotherapy in Canada creates a best-in-class company. The combination of Novamind’s network of mental health clinics and research sites in the U.S. “This transaction offers significant value for Novamind’s shareholders and provides compelling new opportunities for our employees, patients and research partners. This comment from Yaron Conforti, CEO and Co-Founder of Novamind, sums up the potential pros of this deal nicely: The combined company will operate four clinical research sites and a bioanalytical laboratory, as well as several clinical trials.The combined company will operate 13 wellness clinics in North America, with approx revenue of C$10 million (supposedly top in the industry).The price was at a premium of 51% to Novamind’s 20-day volume-weighted average price as of Apshowing that deal was one of sincere courtship rather than down-market predation. Shareholders of Novamind will receive 0.84 of a common share of Numinus for each Novamind share held (known as the “Exchange Ratio”).
The deal is an all-share transaction, for a total consideration of approximately C$26.2 million.
0 kommentar(er)
